Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07
  • Epinephrine Bitartrate: High-Purity Adrenergic Receptor A...

    2026-01-19

    Epinephrine Bitartrate: High-Purity Adrenergic Receptor Agonist for Cardiovascular Research

    Executive Summary: Epinephrine Bitartrate (SKU B1358) from APExBIO is a validated adrenergic receptor agonist with ≥98% purity, supporting rigorous research in adrenergic signaling pathways (APExBIO). The compound's high solubility in water (≥22.9 mg/mL) and DMSO (≥16.66 mg/mL), but insolubility in ethanol, enables flexible assay design. Its primary mechanism is the activation of alpha and beta adrenergic receptors, making it indispensable for cardiovascular and neurobiology studies (epirubicinhcl.com). Well-characterized storage parameters (-20°C) and comprehensive quality documentation (COA, HPLC, NMR, MSDS) enhance scientific reproducibility. This article extends prior scenario-driven guides by integrating recent benchmarks and clarifying misconceptions in sympathetic nervous system research (sb-715992.com).

    Biological Rationale

    Epinephrine Bitartrate is an epinephrine analog designed for in vitro and in vivo research applications. It acts as a potent agonist at both alpha and beta adrenergic receptors, which are G protein-coupled receptors integral to the sympathetic nervous system. Stimulation of these receptors triggers physiological responses such as increased heart rate, vasoconstriction, and metabolic shifts (adrenorphin.net). In cardiovascular research, these effects are crucial for modeling disease states and evaluating pharmacological interventions. The use of Epinephrine Bitartrate enables precise modulation of adrenergic signaling pathways, essential for dissecting the molecular underpinnings of cardiovascular and neurobiological processes (epigeneticsdomain.com).

    Mechanism of Action of Epinephrine Bitartrate

    Epinephrine Bitartrate stimulates adrenergic receptors by mimicking endogenous epinephrine. Its action is mediated via the direct binding and activation of alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. Upon receptor activation, downstream signaling cascades such as cAMP production and phospholipase C activation are triggered, leading to rapid changes in cell physiology. In vascular smooth muscle, alpha-1 receptor activation results in vasoconstriction, while beta-2 receptor activation causes vasodilation in skeletal muscle. In the myocardium, beta-1 receptor activation increases heart rate and contractility. These mechanisms provide an experimental model for studying the interplay between different adrenergic pathways in health and disease (epirubicinhcl.com).

    Evidence & Benchmarks

    • Epinephrine Bitartrate demonstrates ≥98% purity, confirmed by HPLC and NMR, supporting high reproducibility in cell-based assays (APExBIO product page).
    • Water solubility is ≥22.9 mg/mL at 25°C, enabling preparation of concentrated stock solutions for a range of in vitro and in vivo studies (APExBIO).
    • Adrenergic receptor activation by Epinephrine Bitartrate increases heart rate and contractility in mammalian cardiac tissue models, mirroring endogenous epinephrine effects (Cassidy et al. 1986, source).
    • Use of 1:200,000 epinephrine concentration in local anesthetic solutions extends anesthesia duration and decreases systemic toxicity by slowing absorption (Cassidy et al. 1986,source).
    • Beta-adrenergic effects predominate at low systemic concentrations, leading to skeletal muscle vasodilation and increased cardiac output (Cassidy et al. 1986,source).

    Applications, Limits & Misconceptions

    Epinephrine Bitartrate is broadly used in:

    • Cardiovascular disease research for modeling adrenergic-induced hypertension, arrhythmia, and cardiac contractility changes.
    • Sympathetic nervous system research, including studies on stress response and catecholamine signaling.
    • Neurobiology assays targeting adrenergic receptor function and neurotransmitter release.
    • Cell signaling assays for cAMP quantification, receptor desensitization, and downstream kinase activity.

    This article extends prior guides such as this scenario-driven overview by providing updated benchmarks on solubility and purity. It also clarifies the boundaries of applicability compared to prior stability-focused studies, emphasizing experimental reproducibility in cardiovascular disease research.

    Common Pitfalls or Misconceptions

    • Not suitable for chronic dosing in vivo: Epinephrine Bitartrate is primarily validated for acute or short-term exposure models. Chronic administration may lead to receptor desensitization and off-target effects.
    • Incompatible with ethanol: The compound is insoluble in ethanol, making it unsuitable for protocols requiring ethanol-based stock solutions.
    • Instability in solution at room temperature: Prepared solutions are unstable above 0°C for extended periods; long-term storage is not recommended.
    • Not a selective agonist: It activates both alpha and beta adrenergic receptors, precluding use in experiments requiring subtype-selectivity.
    • Potential systemic toxicity: High concentrations or inadvertent systemic administration can cause tachycardia, hypertension, or arrhythmias (Cassidy et al. 1986).

    Workflow Integration & Parameters

    For best results, dissolve Epinephrine Bitartrate in water or DMSO at concentrations up to the solubility limit (water: ≥22.9 mg/mL; DMSO: ≥16.66 mg/mL). Filter-sterilize for cell culture applications. Prepare fresh solutions immediately before use and store at -20°C if short-term storage is necessary. Detailed quality documentation (COA, HPLC, NMR, MSDS) accompanies each batch, ensuring traceability and regulatory compliance (B1358 kit). Shipping on Blue Ice maintains compound integrity during transit. These parameters streamline integration into cell signaling, cardiovascular, and neurobiology workflows, as highlighted in recent Q&A-based optimization guides, which this article updates with new performance and handling data.

    Conclusion & Outlook

    Epinephrine Bitartrate (APExBIO, SKU B1358) is a robust, well-characterized adrenergic receptor agonist that meets the stringent requirements of cardiovascular, neurobiology, and cell signaling research. Its high purity, documented solubility, and validated mechanism enable reproducible, interpretable results. Continuous benchmarking and adherence to rigorous storage and handling protocols are essential for experimental success. Future studies may further dissect receptor subtype contributions and expand applications in translational models (product page).